trending Market Intelligence /marketintelligence/en/news-insights/trending/yFHgtUhfNdRErAo_tebUfg2 content esgSubNav
In This List

Vericel's knee repair implant gets US FDA approval

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Vericel's knee repair implant gets US FDA approval

The U.S. FDA granted approval to Vericel Corp.'s Maci for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients.

Maci is composed of a patient's own cells that are expanded and placed onto a bio-resorbable porcine-derived collagen membrane that is implanted over the area where the defective or damaged tissue was removed.

The safety and efficacy of Maci were shown in a clinical trial designed to demonstrate reduced pain and improved function in comparison to microfracture, an alternative surgical procedure for cartilage repair.